GLP-1 Receptor Agonists and In Vitro Fertilisation (IVF): A Comprehensive Overview

The landscape of reproductive medicine is in a constant state of evolution, with new pharmacological interventions frequently intersecting with established fertility treatments. One of the most significant recent developments in medicine has been the rise of GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide (found in Ozempic and Wegovy) and liraglutide (Victoza and Saxenda). Primarily celebrated for their efficacy in managing type 2 diabetes and promoting significant weight loss, these medications are now at the centre of a critical discussion within the field of assisted reproductive technology (ART), particularly In Vitro fertilisation (IVF). As the prevalence of obesity continues to rise globally, affecting a substantial portion of individuals seeking fertility treatment, the question of whether these powerful weight-loss drugs can improve IVF outcomes has become increasingly pertinent.

IVF is a cornerstone of modern fertility treatment, offering hope to countless individuals and couples struggling to conceive. However, its success is influenced by a multitude of factors, with body weight being one of the most significant. Obesity is well-documented to negatively impact natural fertility and reduce the success rates of IVF. This has sparked intense interest in the potential role of GLP-1 RAs as a pre-conception tool to optimise a patient’s health before embarking on the physically and emotionally demanding IVF journey.

Understanding GLP-1 Receptor Agonists

Before exploring the intersection of GLP-1 RAs and IVF, it is essential to understand what these medications are and how they function. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone produced in the gut in response to food intake. It plays a pivotal role in glucose homeostasis and appetite regulation, acting as a key messenger in the complex interplay between our digestive system and brain.

The Physiological Role of GLP-1

The natural GLP-1 hormone has several crucial functions in the body:

Stimulates Insulin Secretion: When blood sugar levels rise after a meal, GLP-1 stimulates the beta cells in the pancreas to release insulin. This insulin helps cells absorb glucose from the bloodstream, thereby lowering blood sugar. Importantly, this effect is glucose-dependent, meaning it primarily occurs when blood sugar is high, reducing the risk of hypoglycaemia (abnormally low blood sugar).
Suppresses Glucagon Secretion: GLP-1 inhibits the release of glucagon, another pancreatic hormone that signals the liver to release stored glucose. By suppressing glucagon, GLP-1 prevents excessive glucose production, further contributing to blood sugar control.
Slows Gastric Emptying: It slows down the rate at which food leaves the stomach, leading to a prolonged feeling of fullness and satiety after eating.
Acts on the Brain: GLP-1 receptors are also present in the brain, particularly in areas that regulate appetite and food intake. By activating these receptors, GLP-1 helps to reduce hunger and decrease caloric intake.

Mechanism of Action of GLP-1 Receptor Agonists

GLP-1 receptor agonists are synthetic drugs that mimic the action of the natural GLP-1 hormone. However, they are engineered to be much more resistant to degradation by an enzyme called dipeptidyl peptidase-4 (DPP-4), which rapidly breaks down the body’s own GLP-1. This extended duration of action allows the drugs to exert their effects for much longer, from several hours to an entire week, depending on the specific medication.

Available GLP-1 RAs, such as semaglutide, liraglutide, and dulaglutide, are typically administered via subcutaneous injection, with varying frequencies (daily or weekly). An oral formulation of semaglutide is also available. By activating GLP-1 receptors throughout the body, these drugs effectively enhance the body’s natural mechanisms for blood sugar control and appetite suppression, leading to improved glycaemic control in patients with type 2 diabetes and significant weight loss in individuals with obesity.

However, their powerful effects are not without side effects. The most common are gastrointestinal in nature and include nausea, vomiting, diarrhoea, constipation, and abdominal pain. While often transient, these side effects can be significant for some patients and may impact their quality of life and adherence to treatment.

The Link Between Obesity, Infertility, and IVF

The connection between excess body weight and reproductive health is well-established and profoundly significant. Obesity, defined as a Body Mass Index (BMI) of 30 or higher, creates a systemic inflammatory and hormonally disruptive environment that can impair fertility in both women and men, and significantly compromise the success of IVF treatments.

Impact of Obesity on Female Fertility

In women, adipose (fat) tissue is not merely a passive storage depot for energy; it is an active endocrine organ that produces hormones, including oestrogen, and inflammatory cytokines. Excess adipose tissue disrupts the delicate hormonal balance required for normal reproductive function.

Ovulatory Dysfunction: Obesity is a leading cause of anovulation (the absence of ovulation). It is strongly associated with Polycystic Ovary Syndrome (PCOS), a common endocrine disorder characterised by irregular periods and ovulatory dysfunction. The excess androgens and insulin resistance seen in many women with obesity disrupt the hypothalamic-pituitary-ovarian (HPO) axis, which governs the menstrual cycle.
Impaired Oocyte Quality: Research suggests that the metabolic environment in women with obesity, characterised by elevated levels of lipids, insulin, and inflammatory markers, can negatively affect the development and maturation of oocytes (eggs). This can lead to eggs with a lower potential for successful fertilisation and development into healthy embryos.
Reduced Endometrial Receptivity: The endometrium, or the lining of the uterus, must be receptive for an embryo to implant successfully. Obesity can alter the expression of genes and proteins crucial for endometrial receptivity. The chronic low-grade inflammation associated with obesity can create a uterine environment that is less hospitable to an implanting embryo, increasing the risk of implantation failure.

Impact of Obesity on Male Fertility

The adverse effects of obesity on reproduction are not limited to women. In men, excess weight can lead to:

Hormonal Imbalances: Increased adipose tissue leads to higher activity of the aromatase enzyme, which converts testosterone into oestrogen. This can result in lower testosterone levels and higher oestrogen levels, a hormonal profile that is detrimental to sperm production (spermatogenesis).
Decreased Sperm Quality: Numerous studies, including a meta-analysis published in Obesity Reviews, have linked obesity to reduced sperm concentration, lower motility (the ability of sperm to swim), and an increased incidence of DNA damage within the sperm.
Erectile Dysfunction: Obesity is a major risk factor for conditions like cardiovascular disease and type 2 diabetes, which can impair blood flow and nerve function, contributing to erectile dysfunction.

How Obesity Negatively Affects IVF Outcomes

Given its impact on egg, sperm, and uterine health, it is unsurprising that obesity negatively affects virtually every stage of the IVF process. Clinical evidence consistently shows that women with obesity undergoing IVF experience:

Higher Doses of Stimulation Drugs: They often require higher doses of gonadotropins to stimulate their ovaries, increasing treatment costs and potential risks.
Lower Fertilisation Rates: The compromised quality of both eggs and sperm can lead to a lower percentage of eggs successfully fertilising after retrieval.
Poorer Embryo Quality: Fewer embryos may develop to the blastocyst stage, the optimal stage for transfer.
Higher Miscarriage Rates: Even if implantation occurs, the risk of early pregnancy loss is significantly higher in women with obesity.
Decreased Live Birth Rates: The cumulative effect of these challenges results in a substantially lower chance of taking home a baby per IVF cycle.

Recognising these profound impacts, many fertility clinics advise or even mandate weight loss for patients with a high BMI before commencing treatment. This recommendation is supported by research indicating that even a modest weight loss of 5-10% can restore ovulation in some women and improve metabolic health, potentially leading to better IVF outcomes.

Potential Benefits of GLP-1 RAs in IVF

The primary theoretical benefit of using GLP-1 RAs in the context of IVF stems from their proven ability to induce significant weight loss. By addressing the root issue of obesity, these medications could indirectly create a more favourable physiological environment for conception and pregnancy. However, the scientific community is also exploring whether these drugs might have more direct, beneficial effects on reproductive tissues.

Indirect Benefits Through Weight Loss

The most compelling argument for using GLP-1 RAs prior to IVF is their efficacy as weight management tools. By helping patients with obesity achieve meaningful weight loss, these drugs could potentially:

Improve Metabolic Health: Weight loss leads to improved insulin sensitivity, reduced inflammation, and a more balanced hormonal profile. This metabolic improvement could counteract many of the negative effects of obesity on fertility.
Restore Ovulatory Function: In some anovulatory women, particularly those with PCOS, weight loss can be sufficient to restore regular menstrual cycles and spontaneous ovulation, sometimes even negating the need for IVF altogether.
Enhance IVF Outcomes: For those who still require IVF, entering the treatment cycle at a healthier weight could lead to better response to ovarian stimulation, improved egg and embryo quality, and a more receptive uterine lining, ultimately increasing the chances of a live birth.
Reduce Pregnancy Complications: Obesity is a major risk factor for pregnancy complications such as gestational diabetes, pre-eclampsia, and the need for a caesarean section. Pre-conception weight loss can significantly mitigate these risks, leading to a healthier pregnancy for both mother and baby.

Potential Direct Effects on Reproductive Function

Beyond the systemic benefits of weight loss, researchers are investigating whether GLP-1 receptors, which have been identified in reproductive tissues, could mean that these drugs have a direct impact on fertility.

Ovarian Function and Oocyte Quality: Some preliminary animal and in-vitro studies have suggested that GLP-1 RAs might have a direct positive effect on ovarian function. For example, research in animal models of PCOS has indicated that these drugs could reduce androgen levels and improve follicular development. However, it is crucial to stress that this is an emerging area of research, and robust data from human studies is currently lacking. The translation from animal models to human clinical practice is not guaranteed.
Endometrial Receptivity: Similarly, the presence of GLP-1 receptors in the endometrium has led to speculation that GLP-1 RAs could directly influence the uterine lining, potentially improving its receptivity to an implanting embryo. This hypothesis is still largely theoretical and requires rigorous investigation through well-designed clinical trials.

It is imperative to underscore that while these potential benefits are promising, they are not yet proven in the context of IVF in humans. The current enthusiasm is based on logical inference from the effects of weight loss and very early-stage biological research. Large-scale, randomised controlled trials (RCTs) are essential to definitively confirm whether the use of GLP-1 RAs before IVF translates into higher live birth rates and a better safety profile compared to other weight loss strategies or no intervention at all.

Potential Risks and Considerations of GLP-1 RAs in IVF

While the potential benefits are intriguing, the use of GLP-1 RAs in individuals planning a pregnancy raises significant safety concerns and practical considerations. The absence of comprehensive human data on their use during conception and pregnancy necessitates a highly cautious approach. Clinicians and patients must engage in a thorough risk-benefit discussion before considering this path.

Critical Safety Concerns During Pregnancy

The foremost concern is the unknown effect of these drugs on a developing foetus. Current guidance from drug manufacturers and regulatory bodies explicitly advises against their use during pregnancy.

Potential Teratogenic Effects: Animal reproduction studies have raised red flags. For instance, studies on semaglutide in pregnant rats, rabbits, and monkeys showed an increase in structural abnormalities and early pregnancy losses at certain exposure levels. While animal findings do not always translate to humans, they mandate extreme caution. Due to ethical constraints, similar controlled studies cannot be conducted in pregnant women, meaning definitive human data will likely never be available.
Recommended Washout Period: Because of these potential risks, it is universally recommended that women discontinue GLP-1 RAs for a “washout” period before attempting to conceive. For a long-acting drug like semaglutide, the recommended period is at least two months to ensure the drug is completely cleared from the system before conception occurs. This required delay must be factored into the overall fertility treatment timeline.
Lack of Long-Term Data: There is a complete lack of long-term safety data regarding the health of offspring born to mothers who used GLP-1 RAs in the period leading up to conception. The potential for subtle, long-term developmental or metabolic consequences in children is unknown.

Practical Challenges During Treatment

Beyond the critical safety issues, there are practical considerations that can impact a patient’s IVF journey.

Impact of Side Effects: The common gastrointestinal side effects, nausea, vomiting, and diarrhoea, can be severe in some individuals. These symptoms can be physically draining and emotionally taxing, potentially adding another layer of stress to the already challenging IVF process. Severe side effects could also lead to nutritional deficiencies or dehydration, which are undesirable when preparing for pregnancy.
Adherence to Treatment: The combination of side effects and the need for injections can affect a patient’s ability to adhere to the medication regimen consistently. Furthermore, the cost of these medications can be substantial and may not be covered by insurance for weight loss, creating a financial barrier for many.
Potential Drug Interactions: The IVF protocol involves a cocktail of hormonal medications to stimulate the ovaries and prepare the uterus. While no major adverse interactions between GLP-1 RAs and gonadotropins have been reported, this is an under-researched area. Since GLP-1 RAs delay gastric emptying, they could theoretically affect the absorption of any oral medications taken concurrently.

Given these significant unknowns and potential risks, the decision to use a GLP-1 RA before IVF should never be taken lightly. It requires careful, individualised counselling from a medical professional who can weigh the patient’s specific health profile, the severity of their obesity, and their fertility history against the profound lack of safety data in this specific context.

Current Research and Clinical Trials

The scientific and medical communities recognise the urgent need for high-quality evidence to guide the use of GLP-1 RAs in the periconception period. The current landscape is one of active investigation, with several clinical trials underway designed to move beyond theoretical benefits and anecdotal reports to provide robust data on efficacy and safety.

The Landscape of Ongoing Trials

To find the most up-to-date information on this research, clinicians and patients can refer to international clinical trial registries such as ClinicalTrials.gov. A search on this registry reveals a number of ongoing studies specifically investigating the intersection of GLP-1 RAs and fertility.

For example, a prominent study might be designed as a randomised controlled trial (RCT), the gold standard for clinical evidence. In such a trial, women with obesity who are planning to undergo IVF would be randomly assigned to one of several groups:

An intervention group receiving a GLP-1 RA (e.g., semaglutide) plus lifestyle counselling.
A control group receiving a placebo plus lifestyle counselling.
Another control group received only intensive lifestyle counselling (diet and exercise).

Key Research Questions Being Addressed

These trials are designed to answer critical questions that cannot be resolved through observational data alone:

Efficacy: Do women who use GLP-1 RAs prior to IVF have a statistically significantly higher live birth rate compared to those who lose weight through lifestyle changes alone or those who receive a placebo?
Safety: What is the incidence of maternal and neonatal complications in the group using GLP-1 RAs? Are there any adverse signals that emerge during the trial?
Optimal Protocol: What is the ideal duration of treatment with a GLP-1 RA before starting IVF? What is the optimal dose? Is there a specific patient population (e.g., women with PCOS and obesity) that stands to benefit the most?
Mechanisms: Researchers will also analyse biological markers to understand how the drug might be working. This could involve assessing changes in hormone levels, markers of inflammation, oocyte quality, and endometrial gene expression.

The Importance of Patience

While the prospect of these trials is exciting, it is crucial to exercise patience. Rigorous clinical trials take years to conduct, from patient recruitment and treatment to data analysis and publication. Preliminary findings may be presented at medical conferences, but these should be interpreted with caution until the full, peer-reviewed results are available.

Making widespread clinical recommendations based on incomplete or preliminary data would be premature and potentially unsafe. The history of medicine is filled with examples of treatments that seemed promising in theory but were later found to be ineffective or even harmful when subjected to the rigour of an RCT. Therefore, until the results of these ongoing trials are published, the use of GLP-1 RAs for the specific purpose of improving IVF outcomes remains an experimental approach that should be confined to research settings or considered only after exhaustive consultation about the significant unknowns.

Ethical Considerations

The introduction of a powerful class of drugs like GLP-1 RAs into the emotionally charged world of fertility treatment brings with it a host of complex ethical considerations. These go beyond the immediate clinical questions of safety and efficacy, touching upon issues of patient autonomy, equity, and societal pressure. A responsible dialogue about these medications must include a thoughtful examination of these ethical dimensions.

Informed Consent in the Face of Uncertainty

The cornerstone of ethical medical practice is informed consent. A patient must be given all the relevant information about the potential benefits, risks, and alternatives to a treatment before making a decision. In the case of pre-IVF use of GLP-1 RAs, achieving true informed consent is challenging due to the profound lack of safety data.

Counselling on Unknowns: Clinicians have an ethical obligation to be transparent about the significant uncertainties. This means clearly stating that the long-term effects on the child are completely unknown and that animal studies have raised safety concerns. The conversation must move beyond the potential benefit of weight loss to a frank discussion of these risks.
Avoiding Overstatement of Benefits: It is equally important not to overstate the potential benefits. Clinicians must clarify that the hypothesis that these drugs improve IVF outcomes is still under investigation and not yet a proven fact.

Equity and Access

GLP-1 RAs are expensive medications, and access is often limited by insurance coverage and socioeconomic status. This creates a significant ethical concern regarding health disparities.

A Two-Tiered System: If these drugs are eventually proven to be beneficial, their high cost could create a two-tiered system of fertility care, where only those who can afford them have access to a potentially success-boosting intervention. This could exacerbate existing inequalities in IVF outcomes, which are already influenced by socioeconomic factors.
Off-Label Use and Coverage: The use of GLP-1 RAs for pre-conception weight loss is an “off-label” use, meaning it’s not the indication for which the drug was officially approved. This often makes securing insurance coverage even more difficult, placing the full financial burden on the patient.

Societal and Psychological Pressure

Individuals and couples pursuing IVF are often in a vulnerable position, willing to try almost anything to increase their chances of success. This vulnerability can be exploited, intentionally or not.

The “Medicalisation” of Pre-conception Health: There is a risk of over-medicalising the pre-conception period, creating a sense that a “quick fix” drug is superior to the hard work of lifestyle modification.
Pressure on Women: There could be immense pressure on women with obesity to use these drugs, framing their weight as a personal failure that must be corrected pharmacologically to be “worthy” of IVF. This can lead to feelings of guilt and coercion, undermining patient autonomy.

Navigating these ethical challenges requires a patient-centred approach. The focus must be on empowering patients with clear, unbiased information, respecting their autonomy, and ensuring that any decision to use these medications is made freely, without undue pressure, and with a full understanding of the profound uncertainties involved.

Alternative Approaches to Improving IVF Outcomes in Obese Patients

While the discussion around GLP-1 RAs is prominent, it is crucial to remember that they are just one potential tool among many. For decades, clinicians have been managing obesity in patients seeking fertility treatment using a variety of effective, well-researched, and safer methods. These established approaches should remain the foundation of care.

Lifestyle Modification: The First-Line Approach

The safest and most recommended first-line strategy for weight management prior to IVF is comprehensive lifestyle modification. This approach is holistic, empowering, and carries numerous health benefits beyond weight loss, without the risks associated with pharmacology.

Dietary Changes: Working with a registered dietitian is key. The focus should be on creating a sustainable, nutrient-dense eating plan, such as a Mediterranean-style diet, which is rich in fruits, vegetables, lean proteins, and healthy fats. This is not about crash dieting, which can be detrimental to fertility, but about long-term healthy eating habits.
Increased Physical Activity: Regular, moderate exercise has been shown to improve insulin sensitivity, reduce stress, and promote weight loss. Guidelines from organisations like the UK’s National Institute for Health and Care Excellence (NICE) recommend at least 150 minutes of moderate-intensity activity per week.
Behavioural Support: Lasting change often requires psychological and behavioural support. This can help patients address underlying issues related to eating, develop coping strategies, and build a positive relationship with food and their bodies.

Bariatric Surgery

For patients with severe obesity (e.g., BMI > 40, or >35 with co-morbidities) for whom lifestyle changes have not been sufficient, bariatric surgery can be a transformative option. Procedures like gastric bypass or sleeve gastrectomy can lead to substantial and sustained weight loss.

Impact on Fertility: Research, such as studies published in journals like Human Reproduction Update, has shown that the significant weight loss following bariatric surgery can improve or resolve many obesity-related fertility issues, including PCOS and ovulatory dysfunction.
Timing is Crucial: It is vital to note that pregnancy should be postponed for at least 12-18 months after bariatric surgery. This allows for the period of rapid weight loss to stabilise and minimises the risk of nutritional deficiencies that could harm a developing foetus. This necessary delay must be considered, especially for patients with advanced maternal age.

Other Medical Interventions

Other medications have a more established, albeit modest, role in managing specific conditions associated with obesity and infertility.

Metformin: Often used in women with PCOS, metformin is an insulin-sensitising agent that can help regulate menstrual cycles and may have a modest effect on weight. Its safety profile in early pregnancy is much better understood than that of GLP-1 RAs.
Myo-inositol: This nutritional supplement has shown promise in improving oocyte quality and restoring ovulation in women with PCOS, as supported by numerous clinical studies.

Ultimately, the optimal approach requires a multidisciplinary team, including a fertility specialist, an endocrinologist, a dietitian, and a mental health professional. This team can work collaboratively with the patient to develop a personalised, safe, and effective plan to optimise their health before embarking on the IVF journey.

Conclusion

The emergence of GLP-1 receptor agonists represents a paradigm shift in the management of obesity and type 2 diabetes, and their potential application in the field of reproductive medicine is a topic of immense interest and debate. The theoretical benefit is clear: by effectively treating obesity, one of the most significant barriers to fertility and IVF success, these drugs could indirectly improve outcomes for a large and growing patient population. The possibility of direct beneficial effects on reproductive tissues adds another layer of intrigue.

However, this potential must be weighed against a profound lack of evidence and significant safety concerns. The current state of knowledge is defined by uncertainty. Animal studies have raised red flags regarding foetal development, and human data on periconception use is virtually non-existent. The long-term health of children born after maternal exposure to these drugs is completely unknown. Therefore, any consideration of their use before IVF must be approached with extreme caution, guided by a transparent and thorough discussion of these risks versus the unproven benefits.

The journey through IVF is one of hope, science, and deep personal investment. As new pharmacological avenues are explored, the primary ethical obligation must be to “first, do no harm.” This requires a commitment to rigorous scientific inquiry, transparent patient communication, and an individualised approach that prioritises the long-term health and well-being of both the parent and the future child above all else. The future of medicine is promising, but it must be built on a foundation of solid evidence and unwavering patient safety.

References

National Health Service (NHS). Semaglutide. Retrieved from NHS Website
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Medicines for Diabetes. Retrieved from NIDDK Website
Rittenberg, V., et al. Impact of overweight and obesity on assisted reproduction treatment. Journal of Assisted Reproduction and Genetics. Retrieved from SpringerLink
Sermondade, N., et al. Obesity and increased risk for oligozoospermia and azoospermia. Obesity Reviews, 13(4), 337-344. Retrieved from Obesity Reviews
NICE (National Institute for Health and Care Excellence). Overview | Obese adults – lifestyle weight management | Quality standards | NICE. Retrieved from NICE Website
Moran, L. J., et al. Unpacking the infertility-obesity connection: The role of digital technologies in the personalization of fertility treatment. Human Reproduction Update. Retrieved from Oxford Academic
Medicines and Healthcare products Regulatory Agency (MHRA). Retrieved from MHRA Website
ClinicalTrials.gov. Retrieved from ClinicalTrials.gov